Developments in personalised medicine fuel its growth.
A rising prevalence of hormone-related disorders is expected to drive significant growth in the selective estrogen receptor modulators (SERM) market across the seven major markets (7MM) by 2034, according to DelveInsight.
A key driver of the market is the high incidence of hormone receptor-positive breast cancer. Their utility in osteoporosis also supports their broader adoption in geriatric medicine.
“SERMs function by selectively stimulating or inhibiting estrogen receptors in different tissues, offering therapeutic benefits without the widespread side effects of hormone replacement therapy,” the report said.
Developments in personalised medicine for targeted therapies, particularly in oncology and postmenopausal care, are also fuelling the sector’s expansion.
“Next-generation SERMs aim to expand therapeutic applications beyond traditional indications, including cardiovascular health and cognitive disorders in postmenopausal women,” it added.
Moreover, strategic partnerships, licensing deals, and regulatory approvals further drive the market.
7MM = US, Germany, France, Italy, Spain, UK, and Japan.
